Santambrogio Roberto, Barabino Matteo, De Nicola Enrico, Galfrascoli Elisa, Giovenzana Marco, Zappa Marco Antonio
UOC di Chirurgia Generale, ASST Fatebenefratelli Sacco, Piazza Principessa Clotilde 3, 20121, Milan, Italy.
UOC di Chirurgia Epato-bilio-pancreatica e Digestiva, ASST Santi Paolo e Carlo, Università di Milano, Milan, Italy.
Updates Surg. 2020 Jun;72(2):435-443. doi: 10.1007/s13304-020-00759-w. Epub 2020 Apr 3.
Percutaneous thermo-ablation (TA) may be unfeasible for the tumor location: laparoscopic ablation therapies (LATs) are an alternative option. The aim of this study is to assess the efficacy of LATs in the treatment of HCC not eligible for percutaneous TA or surgical resection. LAT was offered to 503 patients fulfilling at least one of the following criteria: (a) patients with a single nodule or up to three nodules smaller than 3 cm not suitable for surgery; (b) patients not suitable for percutaneous TA; (c) short-term recurrence of HCC (< 3 months). Technical success was achieved with one session in 467 patients (93%). One-month mortality and severe morbidity rates were 0.4% and 2.19%, respectively. During a median follow-up of 38.4 months in the remaining 501 patients, 361 (67%) developed intrahepatic recurrence: it appeared as a local tumor progression (LTP) in 74 cases (15%). Subcapsular lesions showed lower LTP rates (p = 0.008), as well as HCC nodules contiguous to viscera (p = 0.012). In the treatment of HCC, LAT has proved to be a safe and effective technique that enables to treat lesions not eligible for percutaneous approach, with a low morbidity rate.
经皮热消融(TA)可能因肿瘤位置而不可行:腹腔镜消融治疗(LAT)是一种替代选择。本研究的目的是评估LAT治疗不适合经皮TA或手术切除的肝癌的疗效。LAT被应用于503例符合以下至少一项标准的患者:(a)有单个结节或最多三个直径小于3 cm的结节且不适合手术的患者;(b)不适合经皮TA的患者;(c)肝癌短期复发(<3个月)。467例患者(93%)单次治疗即取得技术成功。1个月死亡率和严重并发症发生率分别为0.4%和2.19%。在其余501例患者的中位随访38.4个月期间,361例(67%)发生肝内复发:74例(15%)表现为局部肿瘤进展(LTP)。包膜下病变的LTP发生率较低(p = 0.008),与内脏相邻的肝癌结节也是如此(p = 0.012)。在肝癌治疗中,LAT已被证明是一种安全有效的技术,能够治疗不适合经皮治疗的病变,并发症发生率低。